Back to News
Market Impact: 0.2
Revelation Biosciences Consensus Price Target Increased by 600% to $126.74
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
Fintel-compiled aggregate analyst price targets for Revelation Biosciences (NASDAQCM: REVB) were revised to $126.74 per share, up 600.00% from the prior $18.10 estimate dated September 29, 2026. The report provides no share-price reaction or additional context for the revision.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
REVB0.45
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- SpaceX bear flips to big bull because of AI business. Analyst now sees 70% gain
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Williams Trading cuts Deckers Outdoor stock price target on weak DTC trends
- Investing.com’s stocks of the week
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Run Cost-Controlled Financial Research in AllMind Agent Studio